HomeCompareCYBE vs MRK

CYBE vs MRK: Dividend Comparison 2026

CYBE yields 3.70% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $32.3K in total portfolio value
10 years
CYBE
CYBE
● Live price
3.70%
Share price
$54.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$469.91
Full CYBE calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — CYBE vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCYBEMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CYBE + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CYBE pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYBE
Annual income on $10K today (after 15% tax)
$314.81/yr
After 10yr DRIP, annual income (after tax)
$399.42/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MRK beats the other by $8,197.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYBE + MRK for your $10,000?

CYBE: 50%MRK: 50%
100% MRK50/50100% CYBE
Portfolio after 10yr
$41.6K
Annual income
$5,291.84/yr
Blended yield
12.73%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CYBE
Analyst Ratings
2
Buy
2
Hold
Consensus: Buy
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYBE buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCYBEMRK
Forward yield3.70%2.81%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$25.4K$57.7K
Annual income after 10y$469.91$10,113.78
Total dividends collected$4.2K$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: CYBE vs MRK ($10,000, DRIP)

YearCYBE PortfolioCYBE Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,070$370.37$11,213$373.04$143.00MRK
2$12,228$383.19$12,667$512.06$439.00MRK
3$13,480$395.59$14,439$708.14$959.00MRK
4$14,831$407.55$16,640$988.16$1.8KMRK
5$16,288$419.06$19,432$1,394.07$3.1KMRK
6$17,859$430.13$23,057$1,992.90$5.2KMRK
7$19,550$440.74$27,889$2,894.79$8.3KMRK
8$21,369$450.91$34,518$4,286.29$13.1KMRK
9$23,325$460.63$43,912$6,494.35$20.6KMRK
10$25,428$469.91$57,714$10,113.78$32.3KMRK

CYBE vs MRK: Complete Analysis 2026

CYBEStock

CyberOptics Corporation designs, develops, manufactures, and markets high precision sensing technology solutions and system products for inspection and metrology worldwide. It offers products based on multi-reflection suppression (MRS) technology, including multi-function systems for inspection and metrology; MX3000 memory module inspection system; 3D NanoResolution MRS sensor and WX3000 inspection and metrology system for semiconductor wafer and advanced packaging inspection and metrology; high precision 3D and 2D sensors; 3D MRS sensors; SMT electronic assembly alignment sensors; and inspection and metrology systems. The company also provides automated optical inspection (AOI) products; SQ3000 multi-function systems; QX Series 2D AOI products; MX products for inspection of memory modules; SPI Products; and semiconductor wafer and advanced packaging products. In addition, it offers general industrial metrology products and services, such as CyberGage360, a near-line or off-line metrology tool; and 3D scanning and metrology equipment, as well as semiconductor, automatic leveling, automatic gapping, automatic teaching, automatic vibration, WaferSense airborne particle, in-line particle, WaferSense auto multi, WaferSense 300mm auto resistance, and WaferSense auto vibration and leveling sensors. The company sells its products to SMT electronic assembly circuit board manufacturers, end-user customers manufacturing their own circuit boards, semiconductor manufacturers, and outsourced semiconductor assembly and test companies through independent sales representatives and distributors. CyberOptics Corporation was founded in 1984 and is headquartered in Minneapolis, Minnesota.

Full CYBE Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this CYBE vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYBE vs SCHDCYBE vs JEPICYBE vs OCYBE vs KOCYBE vs MAINCYBE vs JNJCYBE vs ABBVCYBE vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.